MIM
QNCX icon

MetLife Investment Management’s Quince Therapeutics QNCX Stock Holding History

MetLife Investment Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-36
Closed -$91K – 2763
2021
Q4 		$91K Hold
36
– – ﹤0.01% 2435
2021
Q3 		$661K Hold
36
– – 0.01% 1369
2021
Q2 		$382K Hold
36
– – ﹤0.01% 1737
2021
Q1 		$260K Hold
36
– – ﹤0.01% 1897
2020
Q4 		$200K Hold
36
– – ﹤0.01% 1985
2020
Q3 		$361K Hold
36
– – ﹤0.01% 1538
2020
Q2 		$334K Buy
36
+9
+33% +$82.5K ﹤0.01% 1603
2020
Q1 		$244K Hold
27
– – ﹤0.01% 1585
2019
Q4 		$300K Buy
+27
New +$163K ﹤0.01% 1749

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MetLife Investment Management's QNCX Position: Q1 2022 in Review

MetLife Investment Management sold out of Quince Therapeutics (QNCX) in Q1 2022, closing a stake of 36 shares — an estimated $91K sold.

MetLife Investment Management first reported a position in QNCX in Q4 2019 and held it in 9 quarters. The position peaked at $661K in Q3 2021. 85 funds tracked by Wall St. Rank hold QNCX as of Q1 2022.

  • MetLife Investment Management reported no remaining Quince Therapeutics position as of Q1 2022 after selling out during the quarter.
  • MetLife Investment Management sold 36 Quince Therapeutics shares in Q1 2022, an estimated $91K.
  • MetLife Investment Management first reported a position in Quince Therapeutics in Q4 2019 and held it in 9 quarters.
  • MetLife Investment Management's Quince Therapeutics position peaked at $661K in Q3 2021.
  • 85 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2022.

Based on MetLife Investment Management's 13F filing for Q1 2022, filed 12 May 2022.